Long-term Observation PMS for Afatinib
Post Marketing Surveillance on Long Term Drug Use of GIOTRIF Tablets in Patients With Epidermal Growth Factor Receptor Mutation-positive Inoperable or Recurrent Non-small Cell Lung Cancer.
Sponsor: Boehringer Ingelheim
Listed as NCT02131259, this observational or N/A phase trial focuses on Carcinoma, Non-Small-Cell Lung and remains completed. Sponsored by Boehringer Ingelheim, it has been updated 10 times since 2014, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
10 versions recorded-
Sep 2025 — Present [monthly]
Completed
-
Sep 2024 — Sep 2025 [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Dec 2021 — Jul 2024 [monthly]
Completed
-
Jan 2021 — Dec 2021 [monthly]
Completed
▶ Show 5 earlier versions
-
Oct 2018 — Jan 2021 [monthly]
Completed
-
Jun 2018 — Oct 2018 [monthly]
Completed
-
Apr 2018 — Jun 2018 [monthly]
Completed
Phase: NA → None
-
Jul 2017 — Apr 2018 [monthly]
Completed NA
Status: Active Not Recruiting → Completed
-
Jan 2017 — Jul 2017 [monthly]
Active Not Recruiting NA
First recorded
May 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Boehringer Ingelheim
For direct contact, visit the study record on ClinicalTrials.gov .